In an adult patient with hemoglobin 16 g/dL, red blood cell count 5.56 ×10⁶/µL, and hematocrit 49.4 %, what does this indicate and what follow‑up management is recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Elevated Hematocrit Requiring Polycythemia Vera Workup

These values meet WHO 2016 diagnostic criteria thresholds for polycythemia vera (PV) and mandate immediate evaluation with JAK2 mutation testing, regardless of patient sex. 1

Diagnostic Significance

The hematocrit of 49.4% exceeds the WHO 2016 major criterion threshold for PV diagnosis. Specifically:

  • Men: Hct >49% or Hgb >16.5 g/dL
  • Women: Hct >48% or Hgb >16 g/dL 1

Your patient's hemoglobin of 16 g/dL combined with Hct 49.4% triggers diagnostic evaluation regardless of whether this is a male or female patient, as the hematocrit alone meets male criteria and approaches female thresholds.

Immediate Workup Algorithm

Step 1: JAK2 Mutation Testing

  • Order JAK2 V617F mutation analysis immediately 1
  • This is the most critical initial test, as JAK2 mutations are present in >95% of PV cases
  • Do not wait for other results before ordering this test 2

Step 2: Serum Erythropoietin Level

  • Low EPO → suggests primary erythrocytosis (PV or other myeloproliferative neoplasm)
  • Normal/elevated EPO → suggests secondary erythrocytosis 3

Step 3: Assess for Secondary Causes

  • Iron studies (ferritin, iron saturation) - iron deficiency can mask PV 4
  • Smoking history and carboxyhemoglobin level
  • Sleep apnea screening
  • Renal imaging if EPO elevated (renal tumors, cysts)
  • Testosterone use history 5

Critical Diagnostic Considerations

Why This Matters for Morbidity/Mortality

PV carries significant thrombotic risk with potential for:

  • Stroke
  • Myocardial infarction
  • Deep vein thrombosis/pulmonary embolism
  • Portal vein thrombosis 6
  • Progression to acute myeloid leukemia (1-2% risk)

Importantly, thrombotic events can occur even with "borderline" hematocrit elevations and may be the presenting feature before overt polycythemia develops 6. One case series documented JAK2-positive PV presenting with portal vein thrombosis despite completely normal hemoglobin and hematocrit 6.

Common Pitfalls to Avoid

Do not dismiss borderline elevations: The 2016 WHO criteria lowered diagnostic thresholds specifically because thrombotic complications occur at these levels 1. Studies show that 2.4% of men and 0.11% of women in the general population meet these new criteria 7, but this does not negate the need for evaluation when values are abnormal.

Do not assume iron deficiency excludes PV: Iron deficiency can mask PV by preventing the hemoglobin from rising further. The guidelines explicitly require iron replacement trials in iron-deficient patients to unmask occult PV 4, 1.

Do not rely solely on hematocrit for risk assessment: While elevated hematocrit triggers diagnosis, thrombotic risk in PV relates to multiple factors beyond viscosity, including platelet activation and leukocytosis 8. The presence of JAK2 mutations and other clonal markers drives thrombotic risk independent of hematocrit levels 8.

If JAK2 Positive: Complete PV Diagnostic Criteria

To confirm PV diagnosis when JAK2 is positive, you need 1:

Major Criteria (all 3 required):

  1. ✓ Hgb >16.5 g/dL (men) or >16 g/dL (women), OR Hct >49% (men) or >48% (women)
  2. Bone marrow biopsy showing hypercellularity with trilineage proliferation
  3. ✓ JAK2 mutation present

Minor Criterion:

  • Subnormal serum erythropoietin level

Diagnosis requires all 3 major criteria OR the first 2 major criteria plus the minor criterion.

If JAK2 Negative

Consider:

  • CALR or MPL mutations (rare in isolated erythrocytosis, more common in essential thrombocythemia)
  • Secondary erythrocytosis causes
  • Congenital erythrocytosis syndromes (especially if young patient or family history) 3
  • Repeat testing in 3-6 months if clinical suspicion remains high

Urgent vs. Routine Evaluation

This requires urgent (within 1-2 weeks) but not emergent evaluation unless the patient has:

  • Symptoms of hyperviscosity (headache, visual changes, dizziness)
  • History of thrombosis
  • Significant thrombocytosis or leukocytosis on the same CBC

The RBC count of 5.56 ×10⁶/µL is elevated and supports the erythrocytosis, making this a true polycythemia rather than spurious elevation from dehydration.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.